Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins

[1]  A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. , 2020, Case Medical Research.

[2]  Jiancong Hu,et al.  Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells , 2019, Journal of experimental & clinical cancer research : CR.

[3]  H. Lenz,et al.  MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.

[4]  F. Greten,et al.  Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. , 2018, Cancer cell.

[5]  Min Liu,et al.  DCLK1 promotes epithelial‐mesenchymal transition via the PI3K/Akt/NF‐κB pathway in colorectal cancer , 2018, International journal of cancer.

[6]  R. Fu,et al.  miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells , 2018, OncoTargets and therapy.

[7]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[8]  Robert A. Weinberg,et al.  EMT in cancer , 2018, Nature Reviews Cancer.

[9]  W. Belloso,et al.  Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study , 2017, Anti-cancer drugs.

[10]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[11]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[12]  Chen Huang,et al.  Regulation of EMT by STAT3 in gastrointestinal cancer (Review). , 2017, International journal of oncology.

[13]  O. Stoetzer,et al.  Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. , 2016, Clinical colorectal cancer.

[14]  B. Driscoll,et al.  Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease , 2016, PloS one.

[15]  Trevor Coward,et al.  An In-Vitro Study , 2016 .

[16]  C. Qian,et al.  Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition , 2015, Carcinogenesis.

[17]  I. Herr,et al.  Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer , 2015, Oncotarget.

[18]  R. Amato,et al.  Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions , 2014, European Journal of Clinical Pharmacology.

[19]  Ahmad Hosseini,et al.  The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  D. Lodygin,et al.  IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. , 2014, The Journal of clinical investigation.

[21]  P. Spallarossa,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction. , 2013, Journal of the American College of Cardiology.

[22]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[23]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[24]  N. Petrelli,et al.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[26]  K. Hemminki,et al.  5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. , 2011, British journal of clinical pharmacology.

[27]  S. Zimeras,et al.  Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up , 2010, American journal of hematology.

[28]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Sasahira,et al.  Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine , 2010, British Journal of Cancer.

[30]  G. Lau,et al.  STAT3 implicated in the development of colon cancer: a step closer for targeted therapy? , 2010, Gastroenterology.

[31]  M. Loriot,et al.  Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Joshua M. Stuart,et al.  Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NFκB and microRNA network , 2010, Molecular Cancer.

[33]  Hong Jiang,et al.  CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity , 2010, Molecular and Cellular Biochemistry.

[34]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[35]  G. Feldmann,et al.  The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer , 2009, Gut.

[36]  R. Osieka,et al.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[37]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[38]  P. Albertsson,et al.  Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis , 2009, Acta oncologica.

[39]  J. Marshall.  Coming of age. , 2008, Surgical infections.

[40]  B. Aggarwal,et al.  Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. , 2007, Cancer research.

[41]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[42]  P. Albertsson,et al.  On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A , 2006, Acta oncologica.

[43]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[44]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[45]  J. Silber,et al.  Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[47]  H. Yoshiji,et al.  Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. , 2002, International journal of oncology.

[48]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[49]  H. Yoshiji,et al.  The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.

[51]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.